Alport Syndrome Clinical Trial
Official title:
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
This international, multi-center, Phase 2/3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with Alport syndrome. The Phase 2 portion of the trial will be open-label and enroll up to 30 patients. The Phase 3 portion of the trial will be double-blind, randomized, placebo-controlled and will enroll up to 180 patients.
This international, multi-center, Phase 2/3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with Alport syndrome. The Phase 2 portion of the trial will be open-label and enroll up to 30 patients. The Phase 3 portion of the trial will be double-blind, randomized, placebo-controlled and will enroll up to 180 patients. Patients in the Phase 2 cohort will receive bardoxolone methyl throughout the study. Patients in the Phase 3 cohort will be randomized 1:1 to either bardoxolone methyl or placebo and randomization will be stratified by baseline albumin to creatinine ratio (ACR). Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration. All patients in the study will follow the same visit and assessment schedule. Following randomization on Day 1, patients will be scheduled to be assessed during treatment at Weeks 1, 2, 4, 6, 8, 12, 24, 36, 48, 52, 64, 76, 88, 100, and 104 and by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients will not receive study drug during a 4-week withdrawal period between Weeks 48 and 52. They will re-start treatment at Week 52 at the same dose they received at Week 48 and will continue study drug treatment through Week 100. Patients will also be scheduled to be assessed at an in person follow up visit at Week 104, four weeks after the end of treatment. Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01602835 -
Human Urine Sample Collection for Alport Nephropathy Biomarker Studies
|
N/A | |
Completed |
NCT01696253 -
Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
|
||
Recruiting |
NCT00481130 -
Alport Syndrome Treatments and Outcomes Registry
|
||
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Recruiting |
NCT05448755 -
A Study of ELX-02 in Patients With Alport Syndrome
|
Phase 2 | |
Recruiting |
NCT06274489 -
A Study to Evaluate Setanaxib in Patients With Alport Syndrome
|
Phase 1/Phase 2 | |
Terminated |
NCT02855268 -
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome
|
Phase 2 | |
Recruiting |
NCT06226896 -
Effects of Dapagliflozin on Progression of Alport Syndrome
|
||
Recruiting |
NCT05927467 -
Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)
|
||
Terminated |
NCT03749447 -
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
|
Phase 3 | |
Recruiting |
NCT06425055 -
Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)
|
Phase 2 | |
Completed |
NCT01705132 -
Urinary Biomarkers of the Progression of Alport Kidney Disease
|
N/A | |
Recruiting |
NCT05267262 -
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
|
Phase 2 | |
Completed |
NCT00622544 -
A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
|
||
Recruiting |
NCT02378805 -
European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
|
||
Not yet recruiting |
NCT05655728 -
Treatment With Metformin in Chinese Children With Alport Syndrome
|
Phase 4 | |
Completed |
NCT00309257 -
Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT05133050 -
Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants
|
N/A | |
Recruiting |
NCT04947813 -
Genotype-Phenotype Correlations in Patients With Alport Syndrome
|